Chaotic sepsis and the magic bullet

Anaesthesia and Intensive Care

Volumn 31, Issue 4, 2003, Pages 446-450

  Cameron, R J ^a   Sleigh, J W ^b  

^a GOSFORD HOSPITAL   (Australia)

^b WAIKATO HOSPITAL   (New Zealand)

Author keywords

Chaos, complexity theory: sepsis, treatment

Indexed keywords

ACTIVATED PROTEIN C; IMMUNOMODULATING AGENT;

ARTICLE; AUTOREGULATION; BIOLOGICAL MODEL; CHAOTIC DYNAMICS; CLINICAL TRIAL; DEATH; DISEASE COURSE; FEEDBACK SYSTEM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; METHODOLOGY; NONLINEAR SYSTEM; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THEORETICAL STUDY; TREATMENT PLANNING;

EID: 0041922635     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0303100414     Document Type: Article

References (31)

1. Mosekilde E. Topics in nonlinear dynamics: applications to physics, biology and economic systems. Singapore: World Scientific, 1996; 237-274.
2. Buchman TG. Physiologic stability and physiologic state. J Trauma 1996; 41:599-605.
3. La Rovere MT, Bigger JT, Marcus FI, et al. Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351:478-484.
4. Godin PJ, Buchman TG. Uncoupling of biological oscillators: A complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Mcd 1996; 24:1107-1116.
5. Goldstein B, Fiser DH, Kelly MM, et al. Decomplexification in critical illness and injury: Relationship between heart rate variability, severity of illness, and outcome. Crit Care Med 1998; 26:352-357.
6. Godin PJ, Fleisher LA, Eidsath A et al. Experimental human endotoxemia increases cardiac regularity: Results from a prospective, randomized, crossover trial. Crit Care Med 1996; 24:1117-1124.
7. Society of Critical Care Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864.
8. Bone RC. Immunologic Dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multi-organ dysfunction syndrome. Ann Intern Med 1996; 125:668-680.
9. Heine H, Rietschel ET, Ulmer AJ. The biology of endotoxin. Mol Biotechnol 2001; 19:279-296.
10. Morrison DC, Silverstein R, Luchi M, Shnyra A. Structure-function relationships of bacterial endotoxins. Contribution to microbiological sepsis. Infect Dis Clin North Am 199; 13:313-340.
11. Slotman GJ, Quinn JV. Multivariate regression modelling for the prediction of inflammation, systemic pressure and end organ function in severe sepsis. Shock 1997; 8:225-231.
12. Buchman TG. Awash in data: the problem of predicting physiology in severe sepsis. Shock 1997; 8:232.
13. Kwiatkowski D. Genetic dissection of the molecular pathogenesis of severe infection. Intensive Care Med 2000; 26:S89-S97.
14. Rixen D. Siegel JH. Friedman HP. Sepsis/SIRS," physiologic classification, severity stratification, relation to cytokine elaboration and outcome prediction in posttrauma critical illness. J Trauma 1996; 41:581-598.
15. Hotchkiss JR, Adams AB, Dries DJ, Marini JJ, Crooke PS. Dynamic behavior during noninvasive ventilation: chaotic support? Am J Respir Crit Care Med 2001; 163:374-378.
16. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999; 13:285-297.
17. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-212.
18. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
19. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the surgical intensive care unit. N Engl J Med 2001; 345:1359-1367.
20. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
21. Bone RC, Balk RA, Fein AM et al. The E5 sepsis study group. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin. Results of a prospective, multicenter, randomized controlled trial. Crit Care Med 1995; 23:994-1005.
22. Derkx B, Wittes J, McCloskey R and the European Pediatric Meningococcal Septic Shock Trial Study Group. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis 1999; 28:770-777.
23. Greenberg RN, Wilson KM, Kunz AY. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected serious, gram-negative sepsis. Crit Care Med 1992; 20:730-735.
24. Greenman RL, Schein RMH, Martin MA et al. XOMA Sepsis study group/ A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-1102.
25. Ziegler EJ, Fisher CJ, Sprung CL et al. HA-1A sepsis study group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized double-blind, placebo-controlled trial. N Eng] J Med 1991; 324:429-436.
26. Bernard GR, Vincent JL, Latterre PF et al. Recombinant human protein C. Worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
27. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030.
28. Arndt P, Abraham E. Immunological therapies of sepsis: experimental therapies. Intensive Care Med 2001; 27;S104-115.
29. Kox WJ. Volk T. Kox SN. Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26 Suppl 1: S124-128.
30. Cohen D. All the world's a net. New Scientist 2002; 2338:22-29.
31. Tak PP. Firestein GS. NF-kappa B: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11.